Pictured: Gary Schwartz & Mark Dickson
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, April 22, 2013

Two clinical trials of targeted therapies led by Memorial Sloan Kettering investigators show promising results against different types of sarcoma.

Pictured: José Baselga
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Monday, April 8, 2013

Memorial Sloan Kettering’s Physician-in-Chief, José Baselga, explains the findings from three studies on new targeted therapies for breast cancer.

Pictured: ESK1 Monoclonal Antibody
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 13, 2013

Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Pictured: Major Trends in Modern Cancer Research Seminar
Video
By Julie Grisham, MS, Science Writer/Editor  |  Friday, March 1, 2013

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Pictured: Charles Sawyers
Honor
By Media Staff  |  Wednesday, February 20, 2013

Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.

Pictured: Charles Sawyers' Laboratory
In the Clinic
By Media Staff  |  Monday, January 7, 2013

The American Society of Clinical Oncology’s notable research advances include the approval of a new drug for men with advanced prostate cancer that was developed and studied by Memorial Sloan Kettering researchers.

Pictured: PET Scan
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 15, 2012

Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Pictured: Ping Chi
Q&A
By Julie Grisham, MS, Science Writer/Editor  |  Friday, November 2, 2012

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Monday, September 17, 2012

When new cancer drugs are shown to be largely ineffective, exceptional cases of good outcome may pave the way for new treatments that could benefit a smaller group of patients.

Pictured: Charles Sawyers & Howard Scher
Announcement
By Memorial Sloan Kettering  |  Friday, August 31, 2012

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

Pictured: Robert Motzer
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Monday, May 21, 2012

Results of an international study indicate that the investigational drug tivozanib is more effective and better tolerated than a currently approved therapy in delaying cancer growth.

Pictured: Robert Motzer
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Tuesday, February 7, 2012

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.

Pictured: Memorial Sloan Kettering logo
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, February 6, 2012

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

Pictured: Charles Sawyers & Howard Scher
In the News
By Media Staff  |  Friday, February 3, 2012

The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.

Pictured: Nancy Lee
In the Clinic
By Eva Kiesler, PhD, Science Writer/Editor  |  Monday, December 19, 2011

People with cancer of the nasopharynx, an area behind the nose, may benefit from a new combination therapy, according to an international study led by Memorial Sloan Kettering radiation oncologist Nancy Y. Lee.

Center News

Stay Informed

Get the latest information about cancer care and research every month.